Cornelis B. Lambalk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cornelis B. Lambalk has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Erik Schoute
2 shared publicationsJ Schoemaker
Institute for Endocrinology, Reproduction and Metabolism IVF Center Vrije Universiteit Hospital Amsterdam The Netherlands
2 shared publicationsJoop Schoemaker
2 shared publications- Peter G. A. Hompes
Department of Obstetrics and Gynaecology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
2 shared publications Roel Schats
2 shared publicationsAlexandra W. van Den Belt-Dusebout
1 shared publication
Latest Publications
- 1 October 2016
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 71 (10) , 601-602
Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer
(Abstracted from JAMA 2016;316:300–312) Previous studies have shown that both exogenous and endogenous estrogens and progestogens increase the risk of breast cancer. it has been suggested that in vitro fertilization (IVF) procedures may increase breast cancer risk.
- 1 October 2016
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 71 (10) , 601-602
Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer
(Abstracted from JAMA 2016;316:300–312) Previous studies have shown that both exogenous and endogenous estrogens and progestogens increase the risk of breast cancer. it has been suggested that in vitro fertilization (IVF) procedures may increase breast cancer risk.
- 30 June 2010
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 20 (6) , 822-830
Blood-borne angiogenic factors and sustained multiple implantation: a comparison of singleton and twin pregnancies
- 30 June 2010
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 20 (6) , 822-830
Blood-borne angiogenic factors and sustained multiple implantation: a comparison of singleton and twin pregnancies
- 1 October 2001
- Published by Cambridge University Press (CUP) in Twin Research
- Vol. 4 (5) , 318-320
Birth Weight Corrected for Gestational Age is Related to the Incidence of Down's Syndrome Pregnancies
Three recent studies reported that early depletion of the primordial follicle pool is likely to be an independent risk factor for Down's syndrome pregnancies. The size of the primordial follicle pool at birth is determined by oogenesis and by the rate of follicle atresia during the intra uterine period. Since intra uterine growth retardation was reported to be associated with a significantly reduced primordial follicle pool at birth, we investigated the possibility of a relation between low birth weight for gestational age and the risk of a Down's syndrome pregnancy. In a case control study, 95 women with a history of a Down's syndrome pregnancy and 85 controls provided information on their own birth weight and length of gestation. Birth weight standard deviation scores, indicating the difference in birth weight from a reference group, were significantly lower in Down's syndrome mothers than in controls. These findings illustrate that the risk of a Down's syndrome pregnancy is related to a low birth weight corrected for gestational age, possibly by a causal relation between intra uterine growth retardation and the size of the primordial follicle pool
- 1 October 2001
- Published by Cambridge University Press (CUP) in Twin Research
- Vol. 4 (5) , 318-320
Birth Weight Corrected for Gestational Age is Related to the Incidence of Down's Syndrome Pregnancies
Three recent studies reported that early depletion of the primordial follicle pool is likely to be an independent risk factor for Down's syndrome pregnancies. The size of the primordial follicle pool at birth is determined by oogenesis and by the rate of follicle atresia during the intra uterine period. Since intra uterine growth retardation was reported to be associated with a significantly reduced primordial follicle pool at birth, we investigated the possibility of a relation between low birth weight for gestational age and the risk of a Down's syndrome pregnancy. In a case control study, 95 women with a history of a Down's syndrome pregnancy and 85 controls provided information on their own birth weight and length of gestation. Birth weight standard deviation scores, indicating the difference in birth weight from a reference group, were significantly lower in Down's syndrome mothers than in controls. These findings illustrate that the risk of a Down's syndrome pregnancy is related to a low birth weight corrected for gestational age, possibly by a causal relation between intra uterine growth retardation and the size of the primordial follicle pool
- Open Access
- 1 June 2001
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 16 (6) , 1270-1273
Are elevated FSH concentrations in the pre-conceptional period a risk factor for Down's syndrome pregnancies?
Recent publications have reported a relation between a decreased ovarian reserve and Down's syndrome pregnancies. Using the data of a case–control study into risk factors for a Down's syndrome pregnancy, we estimated the usefulness of pre-conceptional basal follicle stimulating hormone (FSH) screening (detection rate, false positive rate, positive and negative likelihood ratio, as well as the loss rate of unaffected pregnancies) to identify Down's syndrome pregnancies. The optimal detection rate of pre-conceptional basal FSH screening for Down's syndrome pregnancies was 14%, corresponding to a false positive rate of 5% and a positive likelihood ratio of 2.8. Incorporation of basal FSH screening into the regimen of first trimester serum screening followed by nuchal translucency measurement would increase the detection rate from 85 to 87%. However, basal FSH screening alone or in combination with other screening methods would cause an unacceptably high loss rate of unaffected pregnancies compared with current screening protocols, indicating that routine pre-conception basal FSH screening would not be useful to identify women at risk for a Down's syndrome pregnancy. However, when elevated basal FSH concentrations are diagnosed during subfertility evaluation, an elevated risk for a Down's syndrome pregnancy could be discussed with women who become pregnant.
- 1 June 2001
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 16 (6) , 1270-1273
Open AccessAre elevated FSH concentrations in the pre-conceptional period a risk factor for Down's syndrome pregnancies?
Recent publications have reported a relation between a decreased ovarian reserve and Down's syndrome pregnancies. Using the data of a case–control study into risk factors for a Down's syndrome pregnancy, we estimated the usefulness of pre-conceptional basal follicle stimulating hormone (FSH) screening (detection rate, false positive rate, positive and negative likelihood ratio, as well as the loss rate of unaffected pregnancies) to identify Down's syndrome pregnancies. The optimal detection rate of pre-conceptional basal FSH screening for Down's syndrome pregnancies was 14%, corresponding to a false positive rate of 5% and a positive likelihood ratio of 2.8. Incorporation of basal FSH screening into the regimen of first trimester serum screening followed by nuchal translucency measurement would increase the detection rate from 85 to 87%. However, basal FSH screening alone or in combination with other screening methods would cause an unacceptably high loss rate of unaffected pregnancies compared with current screening protocols, indicating that routine pre-conception basal FSH screening would not be useful to identify women at risk for a Down's syndrome pregnancy. However, when elevated basal FSH concentrations are diagnosed during subfertility evaluation, an elevated risk for a Down's syndrome pregnancy could be discussed with women who become pregnant.
- 1 April 2001
- Published by Elsevier in Fertility and Sterility
- Vol. 75 (4) , 731-736
Natural versus induced twinning and pregnancy outcome: a Dutch nationwide survey of primiparous dizygotic twin deliveries
- 1 April 2001
- Published by Elsevier in Fertility and Sterility
- Vol. 75 (4) , 731-736
Natural versus induced twinning and pregnancy outcome: a Dutch nationwide survey of primiparous dizygotic twin deliveries
- 1 March 2001
- Published by Elsevier in The Lancet
- Vol. 357 (9258) , 735-736
Is there a role for follicle-stimulating-hormone receptor in familial dizygotic twinning?
- 1 March 2001
- Published by Elsevier in The Lancet
- Vol. 357 (9258) , 735-736
Is there a role for follicle-stimulating-hormone receptor in familial dizygotic twinning?
- Open Access
- 1 November 2000
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 15 (11) , 2333-2340
Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study
Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the lowest possible dose of GnRHa should be used. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study to determine the minimal daily dose of triptorelin acetate needed to suppress a premature LH surge during IVF treatment in a long protocol. A total of 240 women (60 in each group) was randomized to either placebo or to one of three doses of triptorelin, i.e. 15, 50 or 100 μg daily. Ovarian stimulation was performed with two or three ampoules of FSH daily. A premature LH surge occurred in 23% of placebo-treated patients, but in none of the triptorelin acetate-treated patients. There were significantly more oocytes and embryos in the 50 and 100 μg triptorelin groups. There was no dose relationship in rates of either implantation, pregnancy, ongoing pregnancy, live birth or baby take-home. In this study we showed that daily administration of 15 μg triptorelin is sufficient to prevent a premature LH surge, and that 50 μg is equivalent to 100 μg in terms of IVF results.
- 1 November 2000
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 15 (11) , 2333-2340
Open AccessDose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study
Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the lowest possible dose of GnRHa should be used. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study to determine the minimal daily dose of triptorelin acetate needed to suppress a premature LH surge during IVF treatment in a long protocol. A total of 240 women (60 in each group) was randomized to either placebo or to one of three doses of triptorelin, i.e. 15, 50 or 100 μg daily. Ovarian stimulation was performed with two or three ampoules of FSH daily. A premature LH surge occurred in 23% of placebo-treated patients, but in none of the triptorelin acetate-treated patients. There were significantly more oocytes and embryos in the 50 and 100 μg triptorelin groups. There was no dose relationship in rates of either implantation, pregnancy, ongoing pregnancy, live birth or baby take-home. In this study we showed that daily administration of 15 μg triptorelin is sufficient to prevent a premature LH surge, and that 50 μg is equivalent to 100 μg in terms of IVF results.
- Open Access
- 1 September 2000
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 6 (5) , 505-518
Direct ovarian effects and safety aspects of GnRH agonists and antagonists
In in-vitro fertilization programmes, gonadotrophin releasing hormone (GnRH) agonists are now routinely used in order to prevent the undesired pre-ovulatory spontaneous luteinizing hormone surge. The first publications are now appearing in which GnRH antagonists are used with the same purpose. More attention should be addressed to the safety aspects of these drugs. This review aims to summarize studies on direct ovarian effects of GnRH agonists and GnRH antagonists in non-primates and primates with respect to the functional and morphological aspects in-vitro as well as in-vivo. We conclude that there is a wide variety of functional and morphological effects of GnRH analogues on the ovary. The sometimes paradoxical effects indicate that a variety of factors may be involved in the various processes. Those factors are: (i) the type and dose of the analogue, (ii) the different regimens of administration, (iii) ovarian status at the time of exposure, (iv) ovarian cell types in in-vitro systems, (v) hormonal pre-treatment of these cultures, (vi) the type of hormonal stimulation added to the in-vitro culture, (vii) further methodological differences in the experiments and finally (viii) physiological variations in GnRH receptor abundance which depends on species and/or timing in the cycle. With the increasing number of patients using GnRH analogues in assisted reproduction treatments, there will be an increasing number of pregnancies exposed to these drugs. So far, there does not appear to be an increased risk of birth defects or pregnancy wastage in human pregnancies exposed to daily low-dose GnRH agonist therapy in the first weeks of gestation.
- 1 September 2000
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 6 (5) , 505-518
Open AccessDirect ovarian effects and safety aspects of GnRH agonists and antagonists
In in-vitro fertilization programmes, gonadotrophin releasing hormone (GnRH) agonists are now routinely used in order to prevent the undesired pre-ovulatory spontaneous luteinizing hormone surge. The first publications are now appearing in which GnRH antagonists are used with the same purpose. More attention should be addressed to the safety aspects of these drugs. This review aims to summarize studies on direct ovarian effects of GnRH agonists and GnRH antagonists in non-primates and primates with respect to the functional and morphological aspects in-vitro as well as in-vivo. We conclude that there is a wide variety of functional and morphological effects of GnRH analogues on the ovary. The sometimes paradoxical effects indicate that a variety of factors may be involved in the various processes. Those factors are: (i) the type and dose of the analogue, (ii) the different regimens of administration, (iii) ovarian status at the time of exposure, (iv) ovarian cell types in in-vitro systems, (v) hormonal pre-treatment of these cultures, (vi) the type of hormonal stimulation added to the in-vitro culture, (vii) further methodological differences in the experiments and finally (viii) physiological variations in GnRH receptor abundance which depends on species and/or timing in the cycle. With the increasing number of patients using GnRH analogues in assisted reproduction treatments, there will be an increasing number of pregnancies exposed to these drugs. So far, there does not appear to be an increased risk of birth defects or pregnancy wastage in human pregnancies exposed to daily low-dose GnRH agonist therapy in the first weeks of gestation.
- 1 October 1998
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 145 (1-2) , 97-102
The endocrinology of dizygotic twinning in the human
- 1 October 1998
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 145 (1-2) , 97-102
The endocrinology of dizygotic twinning in the human